Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement on April 3, 2025 [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.”On Sequoia Capital’s Training Data podcast, our Chief AI Officer @MaxJaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines.Listen to the full podcast at the link below:https://t.co/0ve7jAAZxN ...

Summary of Schrödinger (SDGR) 2025 Conference Call Company Overview - Schrödinger combines physics-based methods with artificial intelligence (AI) and machine learning to accelerate the discovery of novel chemical materials for life sciences and material sciences applications [2][5] - The company has approximately 1,800 global customers, primarily in the life sciences sector, including nearly every academic institution studying chemistry [3][4] Financial Performance - In the previous year, Schrödinger reported $180 million in software revenue, growing at 13% [6] - Drug discovery revenue was $27 million, down from $57 million due to a large milestone payment in 2023 [7] - Q1 revenue reached nearly $60 million, a 63% year-over-year increase, with software revenue at $48.8 million (46% growth) and drug discovery revenue at $10.7 million [8][9] - The company forecasts total software revenue growth of 10% to 15% for the year, with drug discovery revenue expected to recover to $45 million to $50 million [9] Business Model and Revenue Streams - Schrödinger's business model includes software licensing, drug discovery collaborations, and a proprietary pipeline with over eight active programs, three of which are in clinical stages [5][6] - The company benefits from cash inflows from collaborations and equity investments in co-founded companies that have gone public or been acquired [8] Strategic Priorities - The focus is on increasing adoption of computational technology among existing customers rather than acquiring new customers [12] - Enhancements to the platform will enable its use for biologics and predicting toxicology risks, aligning with FDA initiatives to phase out animal testing [12][51] Clinical Programs and Pipeline - The company is advancing three proprietary clinical programs, with data readouts expected in the second half of the year [10][20] - Preliminary efficacy data for SGR1505, a MALT1 inhibitor, shows promising results in heavily pretreated patients [14][15] Collaborations and Partnerships - Recent collaborations include a significant deal with Novartis, which involved a $150 million upfront milestone payment for drug discovery collaboration [33] - The partnership with Novartis has led to a substantial increase in software revenue, with Novartis now among the top tier of customers [36][62] Market Dynamics and Customer Insights - The company has observed no significant cutbacks in R&D spending among large pharmaceutical companies despite macroeconomic challenges [60] - Retention rates among large customers are exceptionally high at 99.9% [61] Competitive Landscape - Schrödinger differentiates itself through its unique combination of physics-based methods and machine learning, with limited direct competition in this niche [72][74] - The company views the current AI boom in drug discovery as beneficial, as it may lead to increased use of structure-based drug design, which aligns with Schrödinger's platform [73][74] Conclusion - Schrödinger is well-positioned for growth with a robust business model, strong financial performance, and strategic collaborations, while also adapting to industry trends and regulatory changes in drug discovery and development.

Financial Performance (Q1 2025) - Total revenue reached $59.6 million, a 63% increase compared to $36.6 million in Q1 2024 [13, 28] - Software revenue grew to $48.8 million, a 46% increase from $33.4 million in Q1 2024 [13, 28] - Drug discovery revenue significantly increased to $10.7 million, a 237% increase compared to $3.2 million in Q1 2024 [13, 28] - Cash and marketable securities increased by 18% to $512.1 million as of March 31, 2025, compared to $435.7 million as of March 31, 2024 [28] - Deferred revenue, current and long term, increased by 265% to $210.0 million as of March 31, 2025, compared to $57.5 million as of March 31, 2024 [28] Financial Guidance (2025) - The company projects software revenue growth of 10% - 15% for the full year 2025 [13, 37] - Drug discovery revenue is expected to be between $45 million and $50 million for 2025 [13, 37] - Operating expense growth is anticipated to be less than 5% for 2025 [13, 37] - Software revenue for the second quarter of 2025 is projected to be in the range of $38 million to $42 million [13, 37] Proprietary Pipeline Milestones - Initial Phase 1 clinical data for SGR-1505 (MALT1) in R/R B-cell malignancies is expected in June 2025 [13, 40] - Initial Phase 1 clinical data for SGR-2921 (CDC7) in R/R AML/MDS is expected in the second half of 2025 [13, 40] - Initial Phase 1 clinical data for SGR-3515 (Wee1/Myt1) in solid tumors is expected in the second half of 2025 [13, 40]

We’re hiring at MLSys 2025!Isomorphic Labs is reimagining drug discovery with the power of AI, and we’re building a world-class MLOps team to do it.Join us as a Machine Learning Performance Engineer to help scale our cutting-edge models that will shape the future of human health.We're looking for:▪︎ Strong working knowledge of HPC and ML Systems.▪︎ Good understanding of GPU and other AI accelerator architectures.▪︎ Strong knowledge of data structures and algorithms.▪︎ Good working knowledge of maths / linea ...

Core Insights - Recursion and Enamine have collaborated to create 10 enriched screening libraries from over 15,000 newly synthesized compounds aimed at accelerating drug discovery against 100 key drug targets in challenging biological areas [1][3] - Enamine's REAL Space contains 64.9 billion make-on-demand molecules, providing a vast chemical library that enhances the drug discovery process when combined with Recursion's AI/ML platform [2][8] - The partnership allows for the development of smaller, focused libraries that outperform traditional high-throughput screening methods, thereby improving the efficiency of drug discovery [2][4] Company Overview - Recursion is a clinical stage TechBio company that utilizes its Recursion OS platform to generate one of the world's largest proprietary biological and chemical datasets, enabling advanced drug discovery [5][6] - Enamine is a Contract Research Organisation with a unique focus on integrated discovery services, offering access to 4.5 million screening compounds and 350,000 building blocks to accelerate drug discovery efforts [7] Technological Advancements - The collaboration leverages Recursion's sophisticated machine-learning algorithms to predict small molecule compatibility with protein targets, enhancing the selection process for promising drug candidates [2][3] - Enamine's REAL Space has been utilized in ultra-large virtual screening campaigns, and this partnership aims to explore its potential across multiple targets at scale [4][9]

Core Points - Absci Corporation granted a non-statutory stock option to a newly-hired non-executive employee for 162,800 shares as part of its 2023 Inducement Plan [1][2] - The exercise price of the stock option is set at $3.42 per share, which is the closing price on the grant date [2] - The stock option has a 10-year term and vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting in approximately equal monthly installments over the next three years [2] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to enhance the development of biologics [3] - The company's Integrated Drug Creation™ platform aims to accelerate the time to clinic and improve the probability of success by optimizing multiple drug characteristics simultaneously [3] - Absci can screen billions of cells weekly, transitioning from AI-designed candidates to wet lab-validated candidates in as little as six weeks [3]

Financial Data and Key Metrics Changes - Total revenue for 2024 was $208 million, a decrease from $217 million in 2023 [30] - Software revenue grew by 13.3% from $159 million to $180 million, with hosted revenue increasing from $20 million to $35 million [30][34] - Q4 total revenue was $88.3 million, an increase of 19% compared to Q4 2023 [18] - Q4 software revenue was $79.7 million, up 16% from Q4 2023 [19] - The net loss for 2024 was $187 million or $2.57 per diluted share, compared to a net income of $41 million or $0.54 per diluted share in 2023 [34] Business Line Data and Key Metrics Changes - The number of software customers with an annual contract value (ACV) greater than $5 million increased from 4 to 8, while those with ACV greater than $1 million rose from 27% to 31% [12] - Total ACV increased by 24% to $191 million [12] - Drug discovery revenue for 2024 was $27 million, down from $58 million in 2023 [32] Market Data and Key Metrics Changes - Hosted revenue contributed 20% of software revenue for 2024, compared to 13% in 2023 [30] - The software gross margin for the year was 79.5%, down from 81.5% in 2023 [32] Company Strategy and Development Direction - The company aims to drive continued increases in the adoption of its computational technology and enterprise informatics platform in 2025 [13] - Plans to release several new products and solutions, including predictive toxicology technology and enhancements to biologics discovery technologies [14] - The company is optimistic about the broad momentum continuing into 2025, with expectations for software revenue growth in the range of 10% to 15% [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for a transformational 2025, with strong operational, financial, and strategic foundations [40] - The company does not expect significant growth from the Chinese market, which represents less than 5% of revenue [39] Other Important Information - The company reported a cash and marketable securities balance of $367 million at the end of Q4 2024, down from $469 million at the end of Q4 2023 [35] - The predictive toxicology project is expected to contribute significantly to revenue in 2025 [41] Q&A Session Summary Question: What is your assumption behind your 2025 drug discovery revenue guidance? - The increase in drug discovery revenue is broad-based, with contributions from various collaborations, including the Novartis partnership [57] Question: How should we think about the cadence for drug discovery revenues? - Drug discovery revenues are likely to be somewhat back-end weighted, with contributions scaling up throughout the year [125] Question: What do customers consider when moving from on-prem to hosted? - The transition to hosted contracts is seen as more seamless for delivering licenses, and the company expects a gradual increase in hosted revenue [76][78] Question: What are the stickiest aspects driving customer retention? - Customer retention is driven by the technology's impact on projects, leading to improved quality and faster development of candidates [90] Question: What is the gating factor for advancing new clinical candidates? - The company is currently evaluating potential partnerships for its clinical assets, with ongoing discussions as data becomes available [114]

Financial Performance - Total revenue for 4Q24 was $88.3 million, a 19% increase compared to $74.1 million in 4Q23[13, 23] - Software revenue for 4Q24 was $79.7 million, a 16% increase compared to $68.7 million in 4Q23[13, 23] - Drug discovery revenue for 4Q24 was $8.7 million, a 58% increase compared to $5.5 million in 4Q23[13, 23] - Total revenue for FY24 was $207.5 million, a 4.2% decrease compared to $216.7 million in FY23[13, 25] - Software revenue for FY24 was $180.4 million, a 13% increase compared to $159.1 million in FY23[13, 25] - Drug discovery revenue for FY24 was $27.1 million, a 53% decrease compared to $57.5 million in FY23[13, 25] 2025 Financial Guidance - The company expects software revenue growth of 10% - 15% in 2025[13, 43] - The company expects drug discovery revenue between $45 million and $50 million in 2025[13, 43] - The company expects operating expense growth to be less than 5% in 2025[13, 43] Key Performance Indicators - Total annual contract value (ACV) increased from $154.2 million in 2023 to $190.8 million in 2024[39] - The number of customers with ACV ≥$5M doubled from 4 in 2023 to 8 in 2024[39]